FMT Changes in the Progression of Chronic Kidney Disease in Patients Undergoing Fecal Microbiota Transplantation (Apr 2024, n=28) "oral FMT in patients with CKD is a safe strategy, does not represent a risk, and has potential benefits"

Fecal Microbiota Transplants

Michael Harrop

Active member
Joined
Jul 6, 2023
Messages
466
Location
USA
https://www.mdpi.com/2072-6643/16/8/1109

Abstract​

Chronic kidney disease (CKD) is a progressive loss of renal function in which gut dysbiosis is involved. Fecal microbiota transplantation (FMT) may be a promising alternative for restoring gut microbiota and treating CKD.

This study evaluated the changes in CKD progression in patients treated with FMT. Patients with diabetes and/or hypertension with CKD clinical stages 2, 3, and 4 in this single-center, double-blind, randomized, placebo-controlled clinical trial (NCT04361097) were randomly assigned to receive either FMT or placebo capsules for 6 months. Laboratory and stool metagenomic analyses were performed. A total of 28 patients were included (15 FMT and 13 placebo).

Regardless of CKD stages, patients responded similarly to FMT treatment. More patients (53.8%) from the placebo group progressed to CKD than the FMT group (13.3%). The FMT group maintained stable renal function parameters (serum creatinine and urea nitrogen) compared to the placebo group. Adverse events after FMT treatment were mild or moderate gastrointestinal symptoms. The abundance of Firmicutes and Actinobacteria decreased whereas Bacteroidetes, Proteobacteria and Roseburia spp. increased in the FMT group. CKD patients showed less disease progression after FMT administration.

The administration of oral FMT in patients with CKD is a safe strategy, does not represent a risk, and has potential benefits.
 
Format correct?
  1. Yes
Back
Top